Human disease cost network analysis

Diseases can be interconnected. In the recent years, there has been a surge of multidisease studies. Among them, HDN (human disease network) analysis takes a system perspective, examines the interconnections among diseases along with their individual properties, and has demonstrated great potential. Most of the existing HDN analyses are based on either molecular information (which may be unreliable and have limited clinical relevance) or phenotypic measures (which may have limited implications for disease management and not directly reflect disease severity). In this study, we take advantage of the uniquely valuable Taiwan NHIRD (National Health Insurance Research Database) data and conduct an HDN analysis of disease treatment cost. Complementing the existing literature, treatment cost can serve as a surrogate of disease severity (and hence be clinically highly relevant) and also directly describe the financial burden of illness (and hence be uniquely informative for disease management). With inpatient and outpatient treatment data on close to 1 million randomly selected subjects and collected during the period of 2000 to 2013, the human disease cost network is constructed using a novel copula-based approach and the weighted correlation-based network construction technique. Extensive analysis is conducted, and the results are found to be biomedically sensible.

[1]  P. Robinson,et al.  The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. , 2008, American journal of human genetics.

[2]  Y. Shih,et al.  Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? , 2012, Value in health regional issues.

[3]  Shannon K. McWeeney,et al.  Cosplicing network analysis of mammalian brain RNA-Seq data utilizing WGCNA and Mantel correlations , 2015, Front. Genet..

[4]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[5]  N. Moutsopoulos,et al.  Low‐Grade Inflammation in Chronic Infectious Diseases , 2006, Annals of the New York Academy of Sciences.

[6]  Yue-chune Lee,et al.  Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003 , 2012, PharmacoEconomics.

[7]  Rob J. Kulathinal,et al.  Large-Scale Discovery of Disease-Disease and Disease-Gene Associations , 2016, Scientific Reports.

[8]  Melissa A. Basford,et al.  Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data , 2013, Nature Biotechnology.

[9]  E. Frohlich,et al.  Diabetes, Hypertension, and Cardiovascular Disease: An Update , 2001, Hypertension.

[10]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[11]  R. L. Fulton,et al.  Multiple system organ failure. The role of uncontrolled infection. , 1980, Archives of surgery.

[12]  O. Hoekenga,et al.  Weighted Correlation Network Analysis (WGCNA) Applied to the Tomato Fruit Metabolome , 2011, PloS one.

[13]  R. Genco,et al.  Periodontal disease and diabetes mellitus: a two-way relationship. , 1998, Annals of periodontology.

[14]  C. Nemeroff,et al.  The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. , 1998, Archives of general psychiatry.

[15]  A. Chang,et al.  A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils) , 2010, Thorax.

[16]  Lei Chen,et al.  WGCNA Application to Proteomic and Metabolomic Data Analysis. , 2017, Methods in enzymology.

[17]  A. Barabasi,et al.  Human symptoms–disease network , 2014, Nature Communications.

[18]  Dag Tjøstheim,et al.  Model selection of copulas: AIC versus a cross validation copula information criterion , 2014 .

[19]  M. Ziégler,et al.  Cost of Illness and Disease Severity in a Cohort of French Patients with Parkinson’s Disease , 1999, PharmacoEconomics.

[20]  B. Craig,et al.  Modeling correlated healthcare costs , 2011, Expert review of pharmacoeconomics & outcomes research.

[21]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[22]  Shuangge Ma,et al.  An Epidemiological Human Disease Network Derived from Disease Co-occurrence in Taiwan , 2018, Scientific Reports.

[23]  C. Lyketsos,et al.  Relationship of cognitive and functional impairment to depressive features in Alzheimer's disease and other dementias. , 1998, The Journal of neuropsychiatry and clinical neurosciences.

[24]  Nataša Pržulj,et al.  The integrated disease network. , 2014, Integrative biology : quantitative biosciences from nano to macro.

[25]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[26]  P. Sorlie,et al.  The Burden of Adult Hypertension in the United States 1999 to 2000: A Rising Tide , 2004, Hypertension.

[27]  A. Barabasi,et al.  A Protein–Protein Interaction Network for Human Inherited Ataxias and Disorders of Purkinje Cell Degeneration , 2006, Cell.

[28]  J. Gazmararian,et al.  The impact of low health literacy on the medical costs of Medicare managed care enrollees. , 2005, The American journal of medicine.

[29]  Jason E. Miller,et al.  Human-Disease Phenotype Map Derived from PheWAS across 38,682 Individuals , 2018, American journal of human genetics.

[30]  Natasa Przulj,et al.  Predicting disease associations via biological network analysis , 2014, BMC Bioinformatics.

[31]  J. Jansson,et al.  Long term trends in control of hypertension in the Northern Sweden MONICA study 1986–2009 , 2015, BMC Public Health.

[32]  A. Rzhetsky,et al.  Probing genetic overlap among complex human phenotypes , 2007, Proceedings of the National Academy of Sciences.

[33]  M. Sklar Fonctions de repartition a n dimensions et leurs marges , 1959 .

[34]  Andrew E Moran,et al.  Cost-effectiveness of hypertension therapy according to 2014 guidelines. , 2015, The New England journal of medicine.

[35]  G. Plante Depression and cardiovascular disease: a reciprocal relationship. , 2005, Metabolism: clinical and experimental.

[36]  S. Horvath,et al.  A General Framework for Weighted Gene Co-Expression Network Analysis , 2005, Statistical applications in genetics and molecular biology.

[37]  Jing Yang,et al.  The human disease network in terms of dysfunctional regulatory mechanisms , 2015, Biology Direct.